159 related articles for article (PubMed ID: 2661820)
21. Inhibition of renin by angiotensinogen peptide fragments containing the hydroxy amino acid residue 5-amino-3-hydroxy-7-methyloctanoic acid.
Johnson RL; Verschoor K
J Med Chem; 1983 Oct; 26(10):1457-62. PubMed ID: 6352942
[TBL] [Abstract][Full Text] [Related]
22. Intramolecularly quenched fluorogenic peptide substrates for human renin.
Oliveira MC; Hirata IY; Chagas JR; Boschcov P; Gomes RA; Figueiredo AF; Juliano L
Anal Biochem; 1992 May; 203(1):39-46. PubMed ID: 1524216
[TBL] [Abstract][Full Text] [Related]
23. Structure-conformation relationships of synthetic peptide inhibitors of human renin studied by resonance energy transfer and molecular modeling.
Epps DE; Mao B; Staples DJ; Sawyer TK
Int J Pept Protein Res; 1988 Jan; 31(1):22-34. PubMed ID: 3284834
[TBL] [Abstract][Full Text] [Related]
24. Renin cleavage of a human kidney renin substrate analogous to human angiotensinogen, H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Ser-OH, that is human renin specific and is resistant to cathepsin D.
Poe M; Wu JK; Lin TY; Hoogsteen K; Bull HG; Slater EE
Anal Biochem; 1984 Aug; 140(2):459-67. PubMed ID: 6385771
[TBL] [Abstract][Full Text] [Related]
25. Peptide inhibitors of renin.
Leckie B; Szelke M; Hallett A; Hughes M; Lever AF; McIntyre G; Morton JJ; Tree M
Clin Exp Hypertens A; 1983; 5(7-8):1221-36. PubMed ID: 6416719
[TBL] [Abstract][Full Text] [Related]
26. Highly sensitive intramolecularly quenched fluorogenic substrates for renin based on the combination of L-2-amino-3-(7-methoxy-4-coumaryl)propionic acid with 2,4-dinitrophenyl groups at various positions.
Paschalidou K; Neumann U; Gerhartz B; Tzougraki C
Biochem J; 2004 Sep; 382(Pt 3):1031-8. PubMed ID: 15233625
[TBL] [Abstract][Full Text] [Related]
27. Renin inhibitors containing statine and 6-aminohexanoic acid. Part III.
Paruszewski R; Tautt J; Dudkiewicz J
Pol J Pharmacol; 1993; 45(1):75-82. PubMed ID: 8401762
[TBL] [Abstract][Full Text] [Related]
28. Syntheses and biological activities of renin inhibitors containing statine analogues.
Nishi T; Saito F; Nagahori H; Kataoka M; Morisawa Y; Yabe Y; Sakurai M; Higashida S; Shoji M; Matsushita Y
Chem Pharm Bull (Tokyo); 1990 Jan; 38(1):103-9. PubMed ID: 2110866
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of human renin. Cyclic peptide analogues containing a D-Phe-Lys-D-Trp sequence.
Dutta AS; Gormley JJ; McLachlan PF; Major JS
J Med Chem; 1990 Sep; 33(9):2560-8. PubMed ID: 2202829
[TBL] [Abstract][Full Text] [Related]
30. Phosphinic peptide analogues as potent inhibitors of Corynebacterium rathayii bacterial collagenase.
Yiotakis A; Lecoq A; Nicolaou A; Labadie J; Dive V
Biochem J; 1994 Oct; 303 ( Pt 1)(Pt 1):323-7. PubMed ID: 7945258
[TBL] [Abstract][Full Text] [Related]
31. Renin inhibitors. Substitution of the leucyl residues of Leu-Leu-Val-Phe-OCH3 with 3-amino-2-hydroxy-5-methylhexanoic acid.
Johnson RL
J Med Chem; 1982 May; 25(5):605-10. PubMed ID: 7045370
[TBL] [Abstract][Full Text] [Related]
32. On the specificity of human renin. Studies with peptide inhibitors.
Poulsen K; Haber E; Burton J
Biochim Biophys Acta; 1976 Dec; 452(2):533-7. PubMed ID: 1009126
[TBL] [Abstract][Full Text] [Related]
33. Inhibitors of renin: present and future.
Haber E
Clin Exp Hypertens A; 1983; 5(7-8):1193-205. PubMed ID: 6357563
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological activity of potent, low molecular weight renin inhibitors.
Sueiras-Diaz J; Jones DM; Szelke M; Deinum J; Svensson L; Westerlund C; Sohtell M
J Pept Res; 1997 Oct; 50(4):248-61. PubMed ID: 9352463
[TBL] [Abstract][Full Text] [Related]
35. Substrate specificity of recombinant human renal renin: effect of histidine in the P2 subsite on pH dependence.
Green DW; Aykent S; Gierse JK; Zupec ME
Biochemistry; 1990 Mar; 29(12):3126-33. PubMed ID: 2186807
[TBL] [Abstract][Full Text] [Related]
36. alpha-Methylproline-containing renin inhibitory peptides: in vivo evaluation in an anesthetized, ganglion-blocked, hog renin infused rat model.
Thaisrivongs S; Pals DT; Lawson JA; Turner SR; Harris DW
J Med Chem; 1987 Mar; 30(3):536-41. PubMed ID: 3546690
[TBL] [Abstract][Full Text] [Related]
37. 1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 2. Synthesis, biological properties and molecular modeling of hydroxyethylene isostere derivatives.
Bradbury RH; Major JS; Oldham AA; Rivett JE; Roberts DA; Slater AM; Timms D; Waterson D
J Med Chem; 1990 Sep; 33(9):2335-42. PubMed ID: 2118184
[TBL] [Abstract][Full Text] [Related]
38. Novel renin inhibitors containing analogues of statine retro-inverted at the C-termini: specificity at the P2 histidine site.
Rosenberg SH; Plattner JJ; Woods KW; Stein HH; Marcotte PA; Cohen J; Perun TJ
J Med Chem; 1987 Jul; 30(7):1224-8. PubMed ID: 3298652
[TBL] [Abstract][Full Text] [Related]
39. Novel inhibitors of human renin. Cyclic peptides based on the tetrapeptide sequence Glu-D-Phe-Lys-D-Trp.
Dutta AS; Gormley JJ; McLachlan PF; Major JS
J Med Chem; 1990 Sep; 33(9):2552-60. PubMed ID: 2202828
[TBL] [Abstract][Full Text] [Related]
40. Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction.
Iizuka K; Kamijo T; Harada H; Akahane K; Kubota T; Umeyama H; Ishida T; Kiso Y
J Med Chem; 1990 Oct; 33(10):2707-14. PubMed ID: 2120440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
